Among them, prior MS therapies and an insufficient washout time; characteristics like gender and weight, which were identified as potentially influencing changes in lymphocyte count and recovery time; and other CYP2C9 reduced-activity phenotypes require further investigation. The gene discussed is CYP2C9; the disease is myeloid sarcoma.